PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1 Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in PD-1 Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ PD-1 Non-Small Cell Lung Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report

* June 2024:- Merck Sharp & Dohme LLC- A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer.
* June 2024:- AstraZeneca- An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON). This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
* DelveInsight's PD-1 Non-Small Cell Lung Cancer pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment.
* The leading PD-1 Non-Small Cell Lung Cancer Companies such as Novartis Pharmaceuticals, Merck Sharp & Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo, Inc., Arcus Biosciences, Inc., IO Biotech, and Cellular Biomedicine Group, Inc., and others.
* Promising PD-1 Non-Small Cell Lung Cancer Therapies such as Durvalumab, AZD9150, AZD6738, REGN2810, Ipilimumab, Cemiplimab, and others.

Stay informed about the cutting-edge advancements in PD-1 Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ PD-1 Non-Small Cell Lung Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile

* Tislelizumab (BGB-A317) - BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages. In pre-clinical studies, binding to FcR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene's immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. stigated in the Phase III stage of development for the treatment of PD-1 Non-Small Cell Lung Cancer.

* Canakinumab: Novartis Pharmarmaceutical

Canakinumab (ACZ885, Ilaris) is a human anti-IL-1 monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of 1 signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. Currently the driug is in phase III stage of development for the treatment of Non-Small Cell Lung Cancer.

* PLB-1004: Avistone Biotechnology

Avistone Biotechnology is developing PLB-1004, an oral EGFR inhibitor being studied in patients with non-small cell lung cancer. In December 2021, Avistone Pharmaceuticals, a clinical-stage biotechnology company focused on precision oncology therapeutics, announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital. The investment will support the combination of Avistone with Pearl Biotechnology Co. Ltd. to create a fully-integrated targeted oncology platform that will address unmet patient needs globally. Based in Beijing, China, Avistone has been committed to the development of precision oncology therapeutics for nearly a decade and has a broad oncology pipeline focused on treatments for lung cancer. The Company's most advanced asset is a c-Met inhibitor in late-stage clinical development for genetically-defined populations of non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Learn more about PD-1 Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking PD-1 Non-Small Cell Lung Cancer Research and development projects @ PD-1 Non-Small Cell Lung Cancer Unmet Needs [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Discover the latest advancements in PD-1 Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* PD-1 Non-Small Cell Lung Cancer Companies- Novartis Pharmaceuticals, Merck Sharp & Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo, Inc., Arcus Biosciences, Inc., IO Biotech, and Cellular Biomedicine Group, Inc., and others.
* PD-1 Non-Small Cell Lung Cancer Therapies- Durvalumab, AZD9150, AZD6738, REGN2810, Ipilimumab, Cemiplimab, and others.
* PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of PD-1 Non-Small Cell Lung Cancer Pipeline on our website @ PD-1 Non-Small Cell Lung Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* PD-1 Non-Small Cell Lung Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* PD-1 Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Canakinumab: Novartis
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* MK-5890: Merck Sharp & Dohme
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* BBP-398: Navire Pharma Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* PD-1 Non-Small Cell Lung Cancer Key Companies
* PD-1 Non-Small Cell Lung Cancer Key Products
* PD-1 Non-Small Cell Lung Cancer- Unmet Needs
* PD-1 Non-Small Cell Lung Cancer- Market Drivers and Barriers
* PD-1 Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
* PD-1 Non-Small Cell Lung Cancer Analyst Views
* PD-1 Non-Small Cell Lung Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pd1-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.